Edesa Biotech, Inc. 8-K

What Happened

• Edesa Biotech (EDSA) filed an 8-K reporting that on May 13, 2026 the Board approved, at the request of CEO Dr. Pardeep Nijhawan, that 90% of his monthly base salary will be issued as fully vested restricted share units (RSUs) under the Company’s 2019 Equity Incentive Compensation Plan.
• The change is made under the terms of Dr. Nijhawan’s Amended and Restated Employment Agreement (dated August 4, 2023, as amended). He will receive the remaining 10% of monthly salary in cash to satisfy local labor and withholding rules. Previously, 50% of his base salary had been paid as RSUs.

Key Details

• Approval date: May 13, 2026; CEO: Dr. Pardeep Nijhawan.
• Equity plan: RSUs issued under the Company’s 2019 Equity Incentive Compensation Plan.
• RSU calculation: Number of RSUs each month = 90% of monthly base salary ÷ fair market value of common shares at month end.
• Vesting/status: RSUs will be fully vested; remaining 10% of salary paid in cash for compliance with local laws.

Why It Matters

• For investors, shifting a larger portion of CEO pay into fully vested RSUs can reduce near-term cash outflow for the company while increasing equity-based compensation, which could affect share count and dilution when RSUs settle.
• The change is a contractual modification under the existing employment agreement disclosed in Edesa’s Form 10-K (filed Dec 12, 2025), so it is a formal, board-approved compensation arrangement rather than an informal commitment.